ABBV
AbbVieBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Stronger-than-expected uptake for new immunology and oncology launches, sustained margins, and continued dividends and buybacks that lift multiples and total return.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.3.
What can break
High debt levels / refinancing risk in adverse market
Momentum
51
Value
62
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $227.23 · Bull $264.73 · Bear $185.31
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-09-27 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $255.08
Why
Momentum51 · Δ7d +3.5
Value62 · Δ7d +0.3
Sentiment54 · Δ7d +4.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
51
34% active weight
Current posture
7d trendSoftening
Δ7d
+3.5
Δ21d
+29.4
Value
62
32% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+0.4
Sentiment
54
33% active weight
Current posture
7d trendImproving
Δ7d
+4.5
Δ21d
+2.9
Why this grade
Composite grade B. Momentum 51.4 / Value 62.3 / Sentiment 54.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$376.2B
Beta
0.34
Shares Out
1.77B
P/E (TTM)
166.1
P/S (TTM)
6.52
P/FCF (TTM)
47.54
Rev YoY
+9.1%
EPS YoY
-88.7%
Gross Margin
+71.2%
Op Margin
+15.2%
Net Debt
$61.59B
Current Ratio
0.72
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology